[EN] SOLID FORMS OF TERT-BUTYL (S)-2-((2S,3R) -1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO-2, 5-DIAZASPIRO [3.4] OCTAN E-5-CARBOXYLATE AND METHODS OF PREPARING THEM<br/>[FR] FORMES SOLIDES DE TERT-BUTYL (S)-2-((2S,3R)-1-AMINO-3-HYDROXY-1-OXOBU TAN-2-YL)-1-OXO -2, 5-DIAZASPIRO[3,4]OCTANE-5-CARBOXYLATE ET LEURS PROCÉDÉS DE PRÉPARATION
申请人:NAUREX INC
公开号:WO2020263847A1
公开(公告)日:2020-12-30
Solid state forms of tert- buty1 (S)-2-((2S,3R)-1 -amino-3-hydroxy- 1-oxobutan-2-y1)- 1 -oxo-2,5- diazaspiro[3.4] octane- 5-carboxylate, pharmaceutical compositions, preparation, and uses thereof.
[EN] PROCESSES AND INTERMEDIATES FOR PRODUCING DIAZASPIRO LACTAM COMPOUNDS<br/>[FR] PROCÉDÉS ET INTERMÉDIAIRES POUR LA PRODUCTION DE COMPOSÉS DE DIAZASPIRO-LACTAME
申请人:NAUREX INC
公开号:WO2020263848A1
公开(公告)日:2020-12-30
Processes for producing diazaspiro lactam compounds and intermediates useful in the processes.
生产二氮螺内酰胺化合物和在生产过程中有用的中间体的方法。
[EN] PROCESS FOR PREPARATION OF LANREOTIDE ACETATE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ACÉTATE DE LANRÉOTIDE
申请人:EMCURE PHARMACEUTICALS LTD
公开号:WO2017178950A1
公开(公告)日:2017-10-19
Disclosed herein is an improved 4+4 solution phase synthesis of Lanreotide acetate. The process comprises coupling of two suitably protected tetrapeptide fragments which on deprotection, oxidation, followed by treatment with acetic acid provides Lanreotide acetate having desired purify.
Peptide ligation by chemoselective aminonitrile coupling in water
作者:Pierre Canavelli、Saidul Islam、Matthew W. Powner
DOI:10.1038/s41586-019-1371-4
日期:2019.7
N-to-C peptide ligation. Our model unites prebiotic aminonitrile synthesis and biological α-peptides, suggesting that short N-acyl peptide nitriles were plausible substrates during early evolution.Prebiotic peptide formation is achieved through chemoselective, high-yielding ligation of α-aminonitriles in water, showing selectivity for α-peptide coupling and tolerance of all proteinogenic amino acid residues
N-methyl-D-aspartate receptor modulators and methods of making and using same
申请人:Naurex, Inc.
公开号:US09994614B2
公开(公告)日:2018-06-12
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.